An overview of long non-coding RNAs in ovarian cancers

Oncotarget

Volumn 7, Issue 28, 2016, Pages 44719-44734

  Meryet Figuière, Matthieu ^a,b,c,d   Lambert, Bernard ^a,b,c,d,e   Gauduchon, Pascal ^a,b,c,d   Vigneron, Nicolas ^a,b,c,d   Brotin, Emilie ^a,b,c,d   Poulain, Laurent ^a,b,c,d   Denoyelle, Christophe ^a,b,c,d  

^a INSERM   (France)

^b NORMANDIE UNIVERSITÉ   (France)

^c UNIVERSITÉ DE CAEN   (France)

^d Calvados Cancer General Registry   (France)

^e CNRS   (France)

Author keywords

IncRNA; Ovarian cancer

Indexed keywords

BMI1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER;

CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; HISTONE MODIFICATION; HUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; RNA BINDING; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; OVARY TUMOR;

BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; MODELS, GENETIC; OVARIAN NEOPLASMS; RNA, LONG NONCODING; RNA, MESSENGER;

EID: 84978630448     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8089     Document Type: Review

References (129)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Coleman RL, Monk BJ, Sood AK, and Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013; 10: 211-224.
3. Di LG, Garofalo M, and Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014; 9: 287-314.
4. Iorio MV and Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012; 18: 215-222.
5. Kinose Y, Sawada K, Nakamura K, and Kimura T. The role of microRNAs in ovarian cancer. Biomed Res Int. 2014; 2014: 249393.
6. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J et al. Landscape of transcription in human cells. Nature. 2012; 489: 101-108.
7. Eddy SR. The ENCODE project: missteps overshadowing a success. Curr. Biol. 2013; 23: R259-R261.
8. Wang KC and Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43: 904-914.
9. Cech TR and Steitz JA. The noncoding RNA revolutiontrashing old rules to forge new ones. Cell. 2014; 157: 77-94.
10. Mercer TR, Dinger ME, and Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10: 155-159.
11. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012; 338: 1435-1439.
12. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, and Prasanth KV. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010; 39: 925-938.
13. de GA, Krell J, Harding V, Stebbing J, and Castellano L. Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN. Mol Cell Biol. 2013; 33: 3976-3982.
14. Tay Y, Rinn J, and PandolfiPP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505: 344-352.
15. Rodriguez A, Griffiths-Jones S, Ashurst JL, and Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004; 14: 1902-1910.
16. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, and Kwok TT. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010; 31: 350-358.
17. Prensner JR and Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1: 391-407.
18. Cheetham SW, Gruhl F, Mattick JS, and Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013; 108: 2419-2425.
19. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q et al. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 2014; 26: 344-357.
20. Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K, Song JJ, Kingston RE, Borowsky M, and Lee JT. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell. 2010; 40: 939-953.
21. Yang YW, Flynn RA, Chen Y, Qu K, Wan B, Wang KC, Lei M, and Chang HY. Essential role of lncRNA binding for WDR5 maintenance of active chromatin and embryonic stem cell pluripotency. Elife. 2014; 3: e02046.
22. Kung JT, Colognori D, and Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013; 193: 651-669.
23. Tsai MC, Manor O, Wan Y, Mosammaparast N, WangJK, Lan F, Shi Y, Segal E, and Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010; 329: 689-693.
24. Sarma K, Cifuentes-Rojas C, Ergun A, Del RA, Jeon Y, White F, Sadreyev R, and Lee JT. ATRX directs binding of PRC2 to Xist RNA and Polycomb targets. Cell. 2014; 159: 869-883.
25. Geisler S and Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 2013; 14: 699-712.
26. Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, Mitra S, Mohammed A, James AR, Hoberg E, Moustakas A, Gyllensten U, Jones SJ et al. MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures. Nat. Commun. 2015; 6: 7743.
27. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, and Chang HY. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007; 129: 1311-1323.
28. Roberts TC, Morris KV, and Weinberg MS. Perspectives on the mechanism of transcriptional regulation by long noncoding RNAs. Epigenetics. 2014; 9: 13-20.
29. Gabory A, Jammes H, and Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays. 2010; 32: 473-480.
30. Gabory A, Ripoche MA, Le DA, Watrin F, Ziyyat A, Forne T, Jammes H, Ainscough JF, Surani MA, Journot L, and Dandolo L. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development. 2009; 136: 3413-3421.
31. Aguilo F, Zhou MM, and Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res. 2011; 71: 5365-5369.
32. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, and PandolfiPP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010; 465: 1033-1038.
33. Guo JU, Agarwal V, Guo H, and Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014; 15: 409.
34. Broderick JA and Zamore PD. Competitive endogenous RNAs cannot alter microRNA function in vivo. Mol Cell. 2014; 54: 711-713.
35. Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao T, Liu Y, Ou J, Wang D, Yao L, Liu S, and Hui N. LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. Hum Mol Genet. 2015; 24: 841-852.
36. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, Lu L, Liu C, Yi JS, Zhang H, Min W, Bennett AM, Gregory RI et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013; 52: 101-112.
37. Wilczynska A and Bushell M. The complexity of miRNAmediated repression. Cell Death. Differ. 2015; 22: 22-33.
38. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-233.
39. Ha M and Kim VN. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014; 15: 509-524.
40. Godnic I, Zorc M, Jevsinek SD, Calin GA, Horvat S, Dovc P, Kovac M, and Kunej T. Genome-wide and species-wide in silico screening for intragenic MicroRNAs in human, mouse and chicken. PLoS. One. 2013; 8: e65165.
41. Du Z, Fei T, Verhaak RG, Su Z, Zhang Y, Brown M, Chen Y, and Liu XS. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol. 2013; 20: 908-913.
42. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-615.
43. Akrami R, Jacobsen A, Hoell J, Schultz N, Sander C, and Larsson E. Comprehensive analysis of long non-coding RNAs in ovarian cancer reveals global patterns and targeted DNA amplification. PLoS One. 2013; 8: e80306.
44. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, and Lawrence JB. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell. 2009; 33: 717-726.
45. Kim YS, Hwan JD, Bae S, Bae DH, and Shick WA. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer. 2010; 10: 576.
46. Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, Guo H, and Yu C. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma. 2015; 62: 432-438.
47. Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, Black JD, and Huang RY. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro. PLoS. One. 2012; 7: e51030.
48. Perez DS, Hoage TR, Pritchett JR, Ducharme-Smith AL, Halling ML, Ganapathiraju SC, Streng PS, and Smith DI. Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet. 2008; 17: 642-655.
49. Qiu J, Ye L, Ding J, Feng W, Zhang Y, Lv T, Wang J, and Hua K. Effects of oestrogen on long noncoding RNA expression in oestrogen receptor alpha-positive ovarian cancer cells. J Steroid Biochem Mol Biol. 2014; 141: 60-70.
50. Zhou M, Wang X, Li J, Hao D, Wang Z, Shi H, Han L, Zhou H, and Sun J. Prioritizing candidate disease-related long non-coding RNAs by walking on the heterogeneous lncRNA and disease network. Mol Biosyst. 2015; 11: 760-769.
51. Liu SP, Yang JX, Cao DY, and Shen K. Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials. Cancer Biol. Med. 2013; 10: 138-141.
52. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, Sui H, Tang Y, Wang Y, Liu N, Ren J, Hou F, and Li Q. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer. 2014; 111: 736-748.
53. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zornig M, MacLeod AR, Spector DL, and Diederichs S. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013; 73: 1180-1189.
54. Han X, Yang F, Cao H, and Liang Z. Malat1 regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis. FASEB J. 2015; 29: 3054-3064.
55. Xu F, Li F, Zhang W, and Jia P. Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression. Tumour. Biol. 2015; 36:9553-8.
56. Denoyelle C, Lambert B, Meryet-Figuiere M, Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH, Gauduchon P, Juin P, and Poulain L. miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death. Dis. 2014; 5: e1445.
57. Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, Sutherland RL, Clark SJ, and Samimi G. ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Mol Cancer. 2014; 13: 3.
58. Cheng Z, Guo J, Chen L, Luo N, Yang W, and Qu X. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. Oncotarget. 2015; 6: 25381-25389. doi: 10.18632/oncotarget.4541.
59. Rangel LB, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, and Morin PJ. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene. 2003; 22: 7225-7232.
60. Silva JM, Boczek NJ, Berres MW, Ma X, and Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol. 2011; 8: 496-505.
61. Xu MD, Qi P, Weng WW, Shen XH, Ni SJ, Dong L, Huang D, Tan C, Sheng WQ, Zhou XY, and Du X. Long noncoding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer. Medicine (Baltimore). 2014; 93: e303.
62. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007; 13: 5745-5755.
63. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014; 512: 82-86.
64. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE, Mushinski JF, Stephens R, and Caplen NJ. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res. 2008; 6: 212-221.
65. Liu E, Liu Z, and Zhou Y. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int. J Clin Exp. Pathol. 2015; 8: 3803-3810.
66. Corney DC, Flesken-Nikitin A, Choi J, and Nikitin AY. Role of p53 and Rb in ovarian cancer. Adv. Exp. Med. Biol. 2008; 622: 99-117.
67. Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, Chen L, Xi Z, Teng H, Wang Z, Li Z, and Liu Y. Knockdown of long noncoding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett. 2015; 359: 75-86.
68. Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI, Scadden DT, and Lee JT. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013; 152: 727-742.
69. Kawakami T, Zhang C, Taniguchi T, Kim CJ, Okada Y, Sugihara H, Hattori T, Reeve AE, Ogawa O, and Okamoto K. Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene. 2004; 23: 6163-6169.
70. Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, Mok SC, Berkowitz RS, and Ng SW. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002; 1: 769-776.
71. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, and Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010; 329: 689-693.
72. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464: 1071-1076.
73. Gutschner T and Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012; 9: 703-719.
74. Qiu JJ, Wang Y, Ding JX, Jin HY, Yang G, and Hua KQ. The long non-coding RNA HOTAIR promotes the proliferation of serous ovarian cancer cells through the regulation of cell cycle arrest and apoptosis. Exp. Cell Res. 2015; 333: 238-248.
75. TeschendorffAE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A et al. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med. 2015; 7: 108.
76. Marsh DJ, Shah JS, and Cole AJ. Histones and their modifications in ovarian cancer-drivers of disease and therapeutic targets. Front Oncol. 2014; 4: 144.
77. Li J, Yang S, Su N, Wang Y, Yu J, Qiu H, and He X. Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/beta-catenin pathway in human ovarian cancer. Tumour. Biol. 2015;
78. Qiu JJ, Lin YY, Ye LC, Ding JX, Feng WW, Jin HY, Zhang Y, Li Q, and Hua KQ. Overexpression of long noncoding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol Oncol. 2014; 134: 121-128.
79. Xing CY, Hu XQ, Xie FY, Yu ZJ, Li HY, Bin Z, Wu JB, Tang LY, and Gao SM. Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia. FEBS Lett. 2015; 589: 1981-1987.
80. Nakano H, Yamada Y, Miyazawa T, and Yoshida T. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int. J Oncol. 2013; 42: 1875-1882.
81. Cheng W, Liu J, Yoshida H, Rosen D, and Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med. 2005; 11: 531-537.
82. Richards EJ, Permuth-Wey J, Li Y, Chen YA, Coppola D, Reid BM, Lin HY, Teer JK, Berchuck A, Birrer MJ, Lawrenson K, Monteiro AN, Schildkraut JM et al. A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. Oncotarget. 2015; 6:34745-57. doi: 10.18632/oncotarget.5784.
83. Congrains A, Kamide K, Ohishi M, and Rakugi H. ANRIL: Molecular Mechanisms and Implications in Human Health. Int. J Mol. Sci. 2013; 14: 1278-1292.
84. Pasmant E, Sabbagh A, Vidaud M, and Bieche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011; 25: 444-448.
85. Gil J and Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 2006; 7: 667-677.
86. Al-Ansari MM, Hendrayani SF, Tulbah A, Al-Tweigeri T, Shehata AI, and Aboussekhra A. p16INK4A represses breast stromal fibroblasts migration/invasion and their VEGF-A-dependent promotion of angiogenesis through Akt inhibition. Neoplasia. 2012; 14: 1269-1277.
87. Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY, and Hua KQ. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int. J Oncol. 2015; 46: 2497-2505.
88. Balch C, Fang F, Matei DE, Huang TH, and Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology. 2009; 150: 4003-4011.
89. Zhou Y, Zhang X, and Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012; 48: R45-R53.
90. Sun M, Xia R, Jin F, Xu T, Liu Z, De W, and Liu X. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol. 2014; 35: 1065-1073.
91. Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, and Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol. 2015; 36:4851-9.
92. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C, and Klibanski A. Activation of p53 by MEG3 non-coding RNA. J Biol Chem. 2007; 282: 24731-24742.
93. Sheng X, Li J, Yang L, Chen Z, Zhao Q, Tan L, Zhou Y, and Li J. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. Oncol Rep. 2014; 32: 277-285.
94. Yan J, Guo X, Xia J, Shan T, Gu C, Liang Z, Zhao W, and Jin S. MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Med Oncol. 2014; 31: 879.
95. Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, and Guo Z. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget. 2015; 6: 2397-2406. doi 10.18632/oncotarget.2963.
96. Jia LF, Wei SB, Gan YH, Guo Y, Gong K, Mitchelson K, Cheng J, and Yu GY. Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma. Int J Cancer. 2014; 135: 2282-2293.
97. Shen W, Song M, Liu J, Qiu G, Li T, Hu Y, and Liu H. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS. One. 2014; 9: e86871.
98. Peng W, Si S, Zhang Q, Li C, Zhao F, Wang F, Yu J, and Ma R. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp. Clin Cancer Res. 2015; 34: 79.
99. Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat. Commun. 2014; 5: 2977.
100. Luo M, Li Z, Wang W, Zeng Y, Liu Z, and Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 2013; 333: 213-221.
101. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, Abu-Lail R, Sorin V, Birman T, de GN, Hochberg A, and Ohana P. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med. 2009; 7: 69.
102. Tanos V, Prus D, Ayesh S, Weinstein D, Tykocinski ML, De-Groot N, Hochberg A, and Ariel I. Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999; 85: 7-11.
103. Yoshimizu T, Miroglio A, Ripoche MA, Gabory A, Vernucci M, Riccio A, Colnot S, Godard C, Terris B, Jammes H, and Dandolo L. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci U S A. 2008; 105: 12417-12422.
104. Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H, and Huang Y. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015; 34:3076-84.
105. Hernandez JM, Elahi A, Clark CW, Wang J, Humphries LA, Centeno B, Bloom G, Fuchs BC, Yeatman T, and Shibata D. miR-675 mediates downregulation of Twist1 and Rb in AFP-secreting hepatocellular carcinoma. Ann Surg Oncol. 2013; 20 Suppl 3: S625-S635.
106. Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, Qian J, Liu N, and You Y. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS One. 2014; 9: e86295.
107. Matouk IJ, Raveh E, Abu-Lail R, Mezan S, Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M, Richler C, Fellig Y, Sorin V et al. Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys Acta. 2014; 1843: 1414-1426.
108. Honig A, Weidler C, Hausler S, Krockenberger M, Buchholz S, Koster F, Segerer SE, Dietl J, and Engel JB. Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res. 2010; 30: 1559-1564.
109. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA, and Mukherjee P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009; 69: 9090-9095.
110. Zhang F, Sui L, and Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol. 2008; 30: 70-74.
111. Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, and Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011; 6: e17918.
112. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF, and Xie D. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 2010; 31: 1576-1583.
113. Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, and Batchu RB. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1)). Pharm Res. 2011; 28: 3079-3090.
114. Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, and Wang Z. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010; 10: 788-795.
115. Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, Kumar S, Cameron D, Sethi S, Ali-Fehmi R, Morris R, Bouwman DL, Munkarah AR et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53. Cancer Lett. 2013; 336: 53-60.
116. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, and Kim S. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14: 2690-2695.
117. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, and Peter ME. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007; 104: 11400-11405.
118. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih I, Zhang Y, Wood W, III, Becker KG, and Morin PJ. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008; 3: e2436.
119. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008; 68: 10307-10314.
120. Lu L, Katsaros D, de la Longrais IA, Sochirca O, and Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007; 67: 10117-10122.
121. Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J, and Wang Z. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2013; 2: e75.
122. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One. 2012; 7: e33729.
123. Tang Z, Ow GS, Thiery JP, Ivshina AV, and Kuznetsov VA. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer. 2014; 134: 306-318.
124. Leyten GH, Hessels D, Jannink SA, Smit FP, de JH, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, and Schalken JA. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014; 65: 534-542.
125. Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, Lemesle G, de GP, Pinet F, and Thum T. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ. Res. 2014; 114: 1569-1575.
126. Li H and Zhang R. Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target. Front Oncol. 2013; 3: 47.
127. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della PA, III, Diaz E, LaFrance LV, Mellinger M, Duquenne C et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492: 108-112.
128. Mizrahi A, Hochberg A, Amiur S, Gallula J, Matouk I, Birman T, Levy T, Ladimir S, and Ohana P. Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences. Int J Clin Exp Med. 2010; 3: 270-282.
129. Mizrahi A, Czerniak A, Ohana P, Amiur S, Gallula J, Matouk I, Abu-Lail R, Birman T, Hochberg A, and Levy T. Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. J Med Case Rep. 2010; 4: 228.